Monitoring Sales and Marketing:

The Conduct Behind the Numbers

Paul J. Silver, Director June 12, 2001

Context



- Pharma, biotech, and research are all center-stage acts with enforcement agencies
- Qui tam litigation will continue in earnest even if the regulatory and enforcement climate becomes more favorable

Challenging Attitudes



*"What do you mean I can't do that? How do you expect me to grow share? I'm just going to lose the business if you make me follow that policy."

Challenging Attitudes



*"What do you mean I can't do that? Our competitors are doing it. I can't compete if you make me follow that policy."

Challenging Attitudes



"Measuring the return on investment of money spent on a physician proves that you're buying a doctor's business."



Gifts

- Monetary Gifts
- Merchandise
- Travel and Entertainment
- Drug Products
- Continuing Education



Grants

- Education
- Training/Preceptorships
- Research
- Phase IV clinical Trials
- Unrestricted Educational Grants



Promotional Programs

- Discount Purchasing Programs
- Rebate Programs
- Patient Assistance Programs
- Cognitive Services Programs



Promotional Strategies

- Cooperative Sales & Marketing Arrangements
- Independent Contractors
 - -Speakers/Writers Bureaus
 - Advisory Panels
- Health Information Collection and Use

Challenging Climate



- Geographically dispersed sales organizations
- Customer expectations
- Shareholder expectations

Solutions



- Embed compliance in routine functions and departmental responsibilities
- Data mine and analyze sales and marketing tracking/reporting databases

Solutions



Engage internal audit to help develop auditing and monitoring protocols and provide staff for periodic audits

Questions?





Paul J. Silver

Health Sciences Litigation Advisory Services

Ernst & Young LLP
Assurance and Advisory
Business Services
Suite 2800
600 Peachtree Street
Atlanta, Georgia 30308-2215

Phone: (404)874-8300
 Direct: (404)817-5766
 Fax: (404)817-4343
 paul.silver@ey.com